American Journal of Kidney Diseases
Volume 52, Issue 5 , Pages 887-896 , November 2008

Hormonal Strategies for Fertility Preservation in Patients Receiving Cyclophosphamide to Treat Glomerulonephritis: A Nonrandomized Trial and Review of the Literature

Received 4 December 2007 ,Accepted 18 June 2008.

References 

  1. De Vita S, Neri R, Bombardieri S. Cyclophosphamide pulses in the treatment of rheumatic diseases: An update. Clin Exp Rheumatol. 1991;9:179–193
  2. Averette HE, Boike GM, Jarrell MA. Effects of cancer chemotherapy on gonadal function and reproductive capacity. CA Cancer J Clin. 1990;40:199–209
  3. Howell SJ, Shalet SM. Testicular function following chemotherapy. Hum Reprod Update. 2001;7:363–369
  4. Pendse S, Ginsburg E, Singh AK. Strategies for preservation of ovarian and testicular function after immunosuppression. Am J Kidney Dis. 2004;43:772–781
  5. Raptopoulou A, Sidiropoulos P, Boumpas DT. Ovarian failure and strategies for fertility preservation in patients with systemic lupus erythematosus. Lupus. 2004;13:887–890
  6. Masala A, Faedda R, Alagna S, et al. Use of testosterone to prevent cyclophosphamide-induced azoospermia. Ann Intern Med. 1997;126:292–295
  7. Faedda R, Satta A, Bosincu L, Pirisi M, Bartoli E. Immune suppressive treatment of membranous glomerulonephritis. J Nephrol. 1995;8:107–112
  8. Matsumoto AM. Effects of chronic testosterone administration in normal men: Safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production. J Clin Endocrinol Metab. 1990;70:282–287
  9. Kreuser ED, Klingmuller D, Thiel E. The role of LHRH-analogues in protecting gonadal functions during chemotherapy and irradiation. Eur Urol. 1993;23:157–163
  10. Waxman JH, Ahmed R, Smith D, et al. Failure to preserve fertility in patients with Hodgkin's disease. Cancer Chemother Pharmacol. 1987;19:159–162
  11. Krause W, Pfluger KH. Treatment with the gonadotropin-releasing hormone agonist buserelin to protect spermatogenesis against cytotoxic treatment in young men. Andrologia. 1989;21:265–270
  12. Blumenfeld Z, Avivi I, Eckman A, Epelbaum R, Rowe JM, Dann EJ. Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma. Fertil Steril. 2008;89:166–173
  13. Blumenfeld Z, Shapiro D, Shteinberg M, Avivi I, Nahir M. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated with chemotherapy. Lupus. 2000;9:401–405
  14. Somers EC, Marder W, Christman GM, Ognenovski V, McCune WJ. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum. 2005;52:2761–2767
  15. Dooley MA, Patterson CC, Susan L, et al. Preservation of ovarian function using depot leuprolide acetate during cyclophosphamide therapy for severe lupus nephritis. Arthritis Rheum. 2000;43:2858;(abstr)
  16. Longhi A, Pignotti E, Versari M, Asta S, Bacci G. Effect of oral contraceptive on ovarian function in young females undergoing neoadjuvant chemotherapy treatment for osteosarcoma. Oncol Rep. 2003;10:151–155
  17. Johnson DH, Linde R, Hainsworth JD, et al. Effect of a luteinizing hormone releasing hormone agonist given during combination chemotherapy on posttherapy fertility in male patients with lymphoma: Preliminary observations. Blood. 1985;65:832–836
  18. Blumenfeld Z, Avivi I, Linn S, Epelbaum R, Ben-Shahar M, Haim N. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. Hum Reprod. 1996;11:1620–1626
  19. Meirow D, Assad G, Dor J, Rabinovici J. The GnRH antagonist cetrorelix reduces cyclophosphamide-induced ovarian follicular destruction in mice. Hum Reprod. 2004;19:1294–1299
  20. Letterie GS. Anovulation in the prevention of cytotoxic-induced follicular attrition and ovarian failure. Hum Reprod. 2004;19:831–837
  21. Sanders JE, Buckner CD, Amos D, et al. Ovarian function following marrow transplantation for aplastic anemia or leukemia. J Clin Oncol. 1988;6:813–818
  22. Practice Committee of the American Society for Reproductive Medicine. Ovarian tissue and oocyte cryopreservation. Fertil Steril. 2004;82:993–998
  23. Chapman RM, Sutcliffe SB. Protection of ovarian function by oral contraceptives in women receiving chemotherapy for Hodgkin's disease. Blood. 1981;58:849–851
  24. Recchia F, Saggio G, Amiconi G, et al. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer. 2006;106:514–523

PII: S0272-6386(08)01115-3

doi: 10.1053/j.ajkd.2008.06.017

American Journal of Kidney Diseases
Volume 52, Issue 5 , Pages 887-896 , November 2008

Article Tools

* Image Usage & Resolution